Adagio Medical Holdings (ADGM) AI Stock Analysis

• Market Cap: $25.84M
• Dividend Yield: N/A
• Average Volume (3M): 152.12K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.46
• Revenue Growth: -70.54%
• EPS Growth: 70.03%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 21,179,638
• 10 Day Avg. Volume: 84,483
• 30 Day Avg. Volume: 152,119
• PEG Ratio: 0.01
• Price to Book (P/B): 1.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.91
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: -162.41
• Enterprise Value/Gross Profit: -21.75
• Enterprise Value/Ebitda: -0.30
• 1Y Price Target: $4.00
• Price Target Upside: 270.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.00 ▼(-7.41% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is primarily constrained by weak financial performance: minimal/zero revenue, persistent losses, and ongoing negative free cash flow with elevated leverage. Technicals provide a partial offset with improving near-term momentum, but valuation is limited by negative earnings and no dividend support.

Positive Factors

Next-generation ULTA shows large procedural benefits

Preclinical evidence of materially faster procedures (50–75% time reduction) and improved handling can drive durable procedural adoption. Reduced OR time and better compatibility with standard labs increase hospital economics and provider uptake, strengthening competitive differentiation over time.

Negative Factors

No commercial revenue and persistent operating losses

Absence of meaningful revenue and negative gross profit indicate the business has not reached commercial scale; persistent operating losses imply the company cannot self-fund operations. This structural weakness increases dependence on external capital and lengthens the time to sustainable profitability.

Adagio Medical Holdings Business Overview & Revenue Model

Company Description

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including...

Read more

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including...

How the Company Makes Money

null...

Adagio Medical Holdings Financial Statement Overview

Breakdown	TTM	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	-143.00K	0.00	269.00K	300.00K	189.00K	270.00K
Gross Profit	-1.07M	-684.00K	-1.67M	-1.01M	-686.00K	-888.00K
EBITDA	-77.03M	-21.89M	-62.48M	-27.41M	-23.04M	-19.60M
Net Income	-74.58M	-25.08M	-53.76M	-38.15M	-23.67M	-19.94M
Balance Sheet
Total Assets	31.55M	43.25M	48.45M	6.83M	8.70M	21.44M
Cash, Cash Equivalents and Short-Term Investments	4.67M	17.11M	20.59M	1.38M	5.55M	18.85M
Total Debt	21.97M	21.76M	16.27M	38.40M	9.80M	0.00
Total Liabilities	32.86M	30.85M	28.54M	138.85M	104.57M	94.06M
Stockholders Equity	-1.31M	12.40M	19.91M	-132.02M	-95.88M	-72.62M
Cash Flow
Free Cash Flow	-23.55M	-19.01M	-31.11M	-25.98M	-22.90M	-20.58M
Operating Cash Flow	-21.99M	-19.01M	-29.46M	-25.65M	-22.41M	-19.31M
Investing Cash Flow	-1.57M	-374.00K	-1.65M	-340.00K	-500.00K	-1.27M
Financing Cash Flow	0.00	16.13M	15.63M	21.88M	9.53M	130.00K

Adagio Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Positive. The current price of 1.08 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 1.02, and below the 200-day MA of 1.25, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 67.15 is Neutral, neither overbought nor oversold. The STOCH value of 65.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADGM.

Adagio Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCH	49 Neutral	$50.17M	-0.55	129.49%	―	-25.18%	-9.71%
ADGM	47 Neutral	$25.84M	-0.69	-210.36%	―	-70.54%	70.03%
PAVM	46 Neutral	$12.98M	>-0.01	20.03%	―	-99.28%	-46.17%
CODX	44 Neutral	$3.67M	-0.55	-70.27%	―	-87.84%	29.16%
VVOS	43 Neutral	$12.04M	-1.57	-335.47%	―	18.76%	60.09%
IINN	41 Neutral	$17.01M	-2.02	-279.06%	―	―	―